186 related articles for article (PubMed ID: 20393344)
1. Metabolic modulation: a new therapeutic target in treatment of heart failure.
Palaniswamy C; Mellana WM; Selvaraj DR; Mohan D
Am J Ther; 2011 Nov; 18(6):e197-201. PubMed ID: 20393344
[TBL] [Abstract][Full Text] [Related]
2. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Rupp H; Zarain-Herzberg A; Maisch B
Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
[TBL] [Abstract][Full Text] [Related]
3. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Lee L; Horowitz J; Frenneaux M
Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
[TBL] [Abstract][Full Text] [Related]
4. Metabolic agents in the management of diabetic coronary patients: a new era.
Marazzi G; Volterrani M; Rosano GM
Int J Cardiol; 2008 Jun; 127(1):124-5. PubMed ID: 18199501
[TBL] [Abstract][Full Text] [Related]
5. Metabolic support for the heart: complementary therapy for heart failure?
Heggermont WA; Papageorgiou AP; Heymans S; van Bilsen M
Eur J Heart Fail; 2016 Dec; 18(12):1420-1429. PubMed ID: 27813339
[TBL] [Abstract][Full Text] [Related]
6. The metabolic treatment of coronary artery disease and heart failure.
Di Napoli P
Curr Pharm Des; 2009; 15(8):826. PubMed ID: 19275645
[No Abstract] [Full Text] [Related]
7. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Inglis S; Stewart S
Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
[TBL] [Abstract][Full Text] [Related]
8. Metabolic agents in the management of diabetic coronary patients: a new era.
Celik T; Kursaklioglu H; Iyisoy A; Jata B
Int J Cardiol; 2008 Jun; 127(1):133-4. PubMed ID: 17561287
[TBL] [Abstract][Full Text] [Related]
9. Modulation of myocardial metabolism: an emerging therapeutic principle.
Horowitz JD; Chirkov YY; Kennedy JA; Sverdlov AL
Curr Opin Cardiol; 2010 Jul; 25(4):329-34. PubMed ID: 20535068
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.
Fang YH; Piao L; Hong Z; Toth PT; Marsboom G; Bache-Wiig P; Rehman J; Archer SL
J Mol Med (Berl); 2012 Jan; 90(1):31-43. PubMed ID: 21874543
[TBL] [Abstract][Full Text] [Related]
11. Metabolic modulation and optimization of energy consumption in heart failure.
Ferrari R; Cicchitelli G; Merli E; Andreadou I; Guardigli G
Med Clin North Am; 2003 Mar; 87(2):493-507, xii-xiii. PubMed ID: 12693736
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of long-chain fatty acid metabolism does not affect platelet aggregation responses.
Willoughby SR; Chirkov YY; Kennedy JA; Murphy GA; Chirkova LP; Horowitz JD
Eur J Pharmacol; 1998 Sep; 356(2-3):207-13. PubMed ID: 9774251
[TBL] [Abstract][Full Text] [Related]
13. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
[TBL] [Abstract][Full Text] [Related]
14. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure.
Fragasso G; Salerno A; Lattuada G; Cuko A; Calori G; Scollo A; Ragogna F; Arioli F; Bassanelli G; Spoladore R; Luzi L; Margonato A; Perseghin G
Heart; 2011 Sep; 97(18):1495-500. PubMed ID: 21700755
[TBL] [Abstract][Full Text] [Related]
15. [Metabolic therapy for heart failure].
Loiacono F; Alberti L; Lauretta L; Puccetti P; Silipigni C; Margonato A; Fragasso G
Recenti Prog Med; 2014; 105(7-8):288-94. PubMed ID: 25072544
[TBL] [Abstract][Full Text] [Related]
16. Cardiac metabolism as a target for the treatment of heart failure.
Taegtmeyer H
Circulation; 2004 Aug; 110(8):894-6. PubMed ID: 15326079
[No Abstract] [Full Text] [Related]
17. The adrenergic-fatty acid load in heart failure.
Opie LH; Knuuti J
J Am Coll Cardiol; 2009 Oct; 54(18):1637-46. PubMed ID: 19850204
[TBL] [Abstract][Full Text] [Related]
18. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Rupp H; Rupp TP; Maisch B
Cardiovasc Res; 2005 Jun; 66(3):423-6. PubMed ID: 15914105
[No Abstract] [Full Text] [Related]
19. Metabolic therapy of heart failure.
Fragasso G; Salerno A; Spoladore R; Bassanelli G; Arioli F; Margonato A
Curr Pharm Des; 2008; 14(25):2582-91. PubMed ID: 18991675
[TBL] [Abstract][Full Text] [Related]
20. [Metabolism and the hypertrophied heart of the elderly].
Rupp H; Rupp TP; Maisch B
Dtsch Med Wochenschr; 2005 Mar; 130(12):726-30. PubMed ID: 15776359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
